OMLONTI (Omidenepag Isopropyl) Patent Expiration, LOE Window & CMS Spending
OMLONTI (Omidenepag Isopropyl) by Ocuvex Therapeutics: FDA Orange Book core substance LOE 2035-06-10 (last listed 2039-07-16), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ocuvex Therapeutics |
| FDA Application & Pathway | N215092 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-06-10 |
| Last Listed Patent or Exclusivity Date | 2039-07-16 |
| Orange Book Patents (*PED Extensions) | 13 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |